STRATEGIC AGREEMENTS	6 Months Ended
Jun. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
STRATEGIC AGREEMENTS	STRATEGIC AGREEMENTS Agreements with Tay Therapeutics Evaluation and Option Agreement In April 2021, the Company entered into an Evaluation and Option Agreement (the “Option Agreement”) with Tay. For a description of the Option Agreement, see Note 3, “Agreements with Tay Therapeutics—Evaluation and Option Agreement” to the condensed consolidated financial statements included in Part I, Item 1 of the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 (the “Q1 Form 10-Q”), filed with the SEC on May 15, 2026, which description is incorporated herein by reference. License for Locally Administered Pan-BD BET Inhibitor Program (Repibresib) On August 6, 2021, the Company exercised its option with respect to the repibresib program and, on August 9, 2021, the parties entered into a License Agreement (the “Repibresib License Agreement”) granting the Company a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of Tay’s pan-BD BET inhibitor compounds in all fields. For a description of the Repibresib License Agreement, see Note 3, “Agreements with Tay Therapeutics—License for Locally Administered Pan-BD BET Inhibitor Program (Repibresib)” to the condensed consolidated financial statements included in Part I, Item 1 of the Company’s Q1 Form 10-Q, which description is incorporated herein by reference. License for Selective BET Inhibitor Program (VYN202) On April 28, 2023, the Company exercised the Oral Option and entered into a license agreement (the "VYN202 License Agreement") with Tay granting the Company a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of Tay’s Oral BETi Compounds in all fields. For a description of the VYN202 License Agreement, see Note 3, “Agreements with Tay Therapeutics—License for Selective BET Inhibitor Program (VYN202)” to the condensed consolidated financial statements included in Part I, Item 1 of the Company’s Q1 Form 10-Q, which description is incorporated herein by reference. Sale of the MST Franchise On January 12, 2022, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Journey pursuant to which the Company sold its MST Franchise to Journey. For a description of the Purchase Agreement, see Note 3, “Sale of the MST Franchise” to the condensed consolidated financial statements included in Part I, Item 1 of the Company’s Q1 Form 10-Q, which description is incorporated herein by reference.

In April 2021, the Company entered into an Evaluation and Option Agreement (the “Option Agreement”) with Tay. For a description of the Option Agreement, see Note 3, “Agreements with Tay Therapeutics—Evaluation and Option Agreement” to the condensed consolidated financial statements included in Part I, Item 1 of the Company’s Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2026 (the “Q1 Form 10-Q”), filed with the SEC on May 15, 2026, which description is incorporated herein by reference.

On August 6, 2021, the Company exercised its option with respect to the repibresib program and, on August 9, 2021, the parties entered into a License Agreement (the “Repibresib License Agreement”) granting the Company a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of Tay’s pan-BD BET inhibitor compounds in all fields. For a description of the Repibresib License Agreement, see Note 3, “Agreements with Tay Therapeutics—License for Locally Administered Pan-BD BET Inhibitor Program (Repibresib)” to the condensed consolidated financial statements included in Part I, Item 1 of the Company’s Q1 Form 10-Q, which description is incorporated herein by reference.

On April 28, 2023, the Company exercised the Oral Option and entered into a license agreement (the "VYN202 License Agreement") with Tay granting the Company a worldwide, exclusive license that is sublicensable through multiple tiers to exploit certain of Tay’s Oral BETi Compounds in all fields. For a description of the VYN202 License Agreement, see Note 3, “Agreements with Tay Therapeutics—License for Selective BET Inhibitor Program (VYN202)” to the condensed consolidated financial statements included in Part I, Item 1 of the Company’s Q1 Form 10-Q, which description is incorporated herein by reference.

On January 12, 2022, the Company entered into an Asset Purchase Agreement (the “Purchase Agreement”) with Journey pursuant to which the Company sold its MST Franchise to Journey. For a description of the Purchase Agreement, see Note 3, “Sale of the MST Franchise” to the condensed consolidated financial statements included in Part I, Item 1 of the Company’s Q1 Form 10-Q, which description is incorporated herein by reference.